ArticleWorld journal of urology2026
Day-case robotic adrenalectomy under ERAS protocol: early outcomes from a single-centre experience.
Article in World journal of urology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTo evaluate the feasibility and outcomes of a day-case robotic adrenalectomy programme implemented within a structured Enhanced Recovery After Surgery (ERAS) framework. MATERIALS AND
methodsA retrospective analysis was conducted of all patients who underwent day-case robotic adrenalectomy between November 2023 and March 2025. Procedures were performed via a transperitoneal approach using the da Vinci Xi
resultsThirteen patients were included. The median age was 49.0 years (46.0-60.0), and the median BMI was 30.0 kg/m² (28.0-36.5). Most patients were male (61.5%, n = 8), all were ASA grade 2, and 69.2% (n = 9) had an ECOG performance status of 0. The median estimated blood loss was 10.0 mL (5.0-10.0) and the median operative time was 56.0 min (30.5-75.0 min). A history of prior abdominal surgery was present in 38.5% of patients (n = 5). Indications included primary hyperaldosteronism (69.2%, n = 9), androgen-producing tumour (n = 1), RCC metastasis (n = 1), and adrenocortical carcinoma (n = 2). No intraoperative or postoperative complications occurred, no patients required readmission, and the median EVAN-G score was 94 (91-96). On preoperative imaging, the median tumour size was 16.0 mm (13.0-26.5 mm). Postoperative pathological analysis reported a median adrenal gland size of 63.0 mm (50.0-72.5 mm) and a median lesion size of 15.0 mm (9.0-22.5 mm).
conclusionDay-case robotic adrenalectomy performed under an ERAS protocol is safe and well-tolerated in selected patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.